Fruquintinib

Specifications

1194506-26-7CAS Number

962-485-3EC Number

6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamideIUPAC Name

C21H19N3O5Chemical Formula

393.4 g/molMolecular Weight

Fruquintinib; 1194506-26-7; HMPL-013; Fruzaqla; HMPL013; 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide; fruquintinibum; Elunate; 49DXG3M5ZW; 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide; 6-(6,7-dimethoxyquinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide; 3-Benzofurancarboxamide, 6-((6,7-dimethoxy-4-quinazolinyl)oxy)-N,2-dimethyl-; 3-Benzofurancarboxamide, 6-[(6,7-dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-; 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethyl-1-benzofuran-3-carboxamide; RefChem:141565; VEGFR-1/2/3 Inhibitor HMPL-013; Fruquintinib [WHO-DD]; 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide; 6-[(6,7-Dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-3-benzofurancarboxamide; Fruquintinib [USAN]; MFCD28502149; UNII-49DXG3M5ZW; 6-[(6,7-Dimethoxyquinazolin-4-yl)oxy]-N,2-dimethylbenzofuran-3-carboxamide; Fruzaqla (TN); Fruquintinib (Standard); Fruquintinib (JAN/USAN); FRUQUINTINIB [INN]; Fruquintinib; HMPL-013; Fruquintinib (HMPL-013); Fruquintinib (HMPL-013)?; SCHEMBL947183; Fruquintinib [USAN:WHO-DD]; GTPL9428; orb1226831; orb1305210; CHEMBL4303214; SCHEMBL29366206; SCHEMBL29516397; BALLNEJQLSTPIO-UHFFFAOYSA-N; CHEBI:229221; DTXSID201358935; GLXC-90366; HMS5085C11; EX-A2262; BDBM50637221; HY-19912R; NSC801000; NSC829498; s5667; WHO 10348; AKOS026750586; CCG-268573; CS-5558; DB11679; NSC-801000; NSC-829498; SB17123; NCGC00481603-01; NCGC00481603-02; AS-73141; BP-43650; FF137674; HY-19912; SY372441; NS00073373; T2656; C71641; D11977; F826282; BRD-K70504253-001-01-3; Q27259271; 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-benzofuran-3-carboxamideSynonyms